IDEXX Laboratories, Inc. $IDXX Shares Sold by AEGON ASSET MANAGEMENT UK Plc

AEGON ASSET MANAGEMENT UK Plc reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,068 shares of the company’s stock after selling 1,247 shares during the quarter. AEGON ASSET MANAGEMENT UK Plc’s holdings in IDEXX Laboratories were worth $17,636,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in IDXX. Virtus Advisers LLC acquired a new position in IDEXX Laboratories in the 3rd quarter valued at $26,000. Park Place Capital Corp acquired a new position in IDEXX Laboratories in the 4th quarter valued at $29,000. WealthCollab LLC acquired a new position in IDEXX Laboratories in the 2nd quarter valued at $30,000. J.Safra Asset Management Corp acquired a new position in IDEXX Laboratories in the 3rd quarter valued at $31,000. Finally, Salomon & Ludwin LLC acquired a new position in IDEXX Laboratories in the 3rd quarter valued at $35,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Sophie V. Vandebroek sold 1,464 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the sale, the director directly owned 648 shares of the company’s stock, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP George Fennell sold 11,345 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total value of $7,337,038.40. Following the sale, the executive vice president directly owned 9,823 shares of the company’s stock, valued at $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 45,957 shares of company stock worth $29,862,109. 0.79% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Barclays reduced their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Stifel Nicolaus cut their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Piper Sandler cut their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $760.00.

IDEXX Laboratories Stock Up 0.9%

Shares of NASDAQ:IDXX opened at $565.93 on Friday. The business has a 50-day moving average price of $594.81 and a 200 day moving average price of $652.99. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $44.95 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 3.41 and a beta of 1.72. IDEXX Laboratories, Inc. has a 12-month low of $427.70 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the company earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.54 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.